{
    "nctId": "NCT06445400",
    "briefTitle": "A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer",
    "officialTitle": "A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Sign the informed consent form voluntarily and follow the protocol requirements;\n2. Gender is not limited;\n3. Age \u226518 years old and \u226475 years old;\n4. Expected survival time for 3 months or more;\n5. Patients with histologically and/or cytologically confirmed unresectable locally advanced or metastatic HER2-positive breast cancer;\n6. Consent to provide archived tumor tissue samples or fresh tissue samples from the primary or metastatic lesions;\n7. At least one measurable lesion meeting the RECIST v1.1 definition was required;\n8. Physical condition score ECOG 0 or 1 ;\n9. The toxicity of previous antineoplastic therapy has returned to \u2264 grade 1 as defined by NCI-CTCAE v5.0;\n10. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n11. No blood transfusion, no colony-stimulating factor, and no albumin are allowed within 14 days before the first use of the study drug, and the organ function level must meet the requirements;\n12. Blood coagulation function: international standardization ratio (INR) 1.5 or less, and the part activated clotting time (APTT) live enzymes acuities were 1.5 x ULN;\n13. Urinary protein \u22642+ or \u22641000mg/24h;\n14. Fertile female subjects, or male subjects with fertile partners, must use highly effective contraception from 7 days before the first dose until 7 months after the end of the dose. Female subjects of childbearing potential had to have a negative serum pregnancy test within 7 days before the first dose.\n\nExclusion Criteria:\n\n1. Received chemotherapy with mitomycin C and nitrosourea within 6 weeks before the first dose, received surgery within 4 weeks before the first dose, and received endocrine therapy within 2 weeks before the first dose;\n2. Patients with locally advanced or metastatic disease who have received previous systemic therapy;\n3. Had received prior ADC drug therapy with camptothecin derivative as toxin;\n4. Screening within the first half of the serious heart, cerebrovascular disease;\n5. Complicated with pulmonary diseases leading to severe impairment of lung function;\n6. A history of ILD/interstitial pneumonia requiring steroid therapy, current ILD/interstitial pneumonia, or suspected ILD;\n7. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;\n8. Other primary malignancies diagnosed within 5 years before the first dose;\n9. Poorly controlled hypertension;\n10. Patients with active central nervous system metastases;\n11. Need treatment intervention of unstable thrombotic events, except infusion related thrombosis;\n12. Patients with a history of allergy to recombinant humanized antibodies or to any excipients of the trial drug;\n13. Had received more than the following cumulative doses of anthracyclines;\n14. Systemic corticosteroids or immunosuppressive agents were required within 2 weeks before study dosing;\n15. Patients with massive or symptomatic effusions or poorly controlled effusions;\n16. Severe systemic infection within 4 weeks before screening;\n17. Active autoimmune and inflammatory diseases;\n18. Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;\n19. Previous history of allogeneic stem cell, bone marrow or organ transplantation;\n20. A history of severe neurological or psychiatric illness;\n21. Pregnancy or lactation women;\n22. Patients who were deemed by the investigator to be ineligible for participation in the study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}